Analysis of Serum MicroRNA-122 Expression at Different Stages of Chronic Hepatitis B Virus Infection

Autor: Wenjun Liu, Xinxiang He, Fei Huang
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Liver Cirrhosis
Serum
Cirrhosis
Biopsy
Gastroenterology
Polymerase Chain Reaction
0302 clinical medicine
Medicine
030212 general & internal medicine
Hepatitis B e Antigens
Stage (cooking)
Liver injury
medicine.diagnostic_test
Liver Diseases
virus diseases
General Medicine
Middle Aged
Viral Load
HBeAg
Liver
Liver biopsy
Disease Progression
psychological phenomena and processes
Research Article
Adult
Gene Expression Regulation
Viral

Genetic Markers
medicine.medical_specialty
Hepatitis B virus
Article Subject
education
behavioral disciplines and activities
General Biochemistry
Genetics and Molecular Biology

Virus
03 medical and health sciences
Young Adult
Hepatitis B
Chronic

Chronic hepatitis
Internal medicine
mental disorders
Humans
Serum microrna
General Immunology and Microbiology
business.industry
medicine.disease
digestive system diseases
MicroRNAs
030104 developmental biology
DNA
Viral

business
Biomarkers
Zdroj: BioMed Research International
BioMed Research International, Vol 2021 (2021)
ISSN: 2314-6141
2314-6133
Popis: Objective. To investigate the expression of microRNA-122 (miR-122) in the progression of chronic hepatitis B virus- (HBV-) infected liver diseases, thus determining the role of serum miR-122 as a marker of HBV-caused liver injury. Methods. Sera were collected from patients with different stages of HBV infection ( n = 63 ) and healthy volunteers ( n = 11 ). And the serum miR-122 levels were detected using RT-qPCR. Moreover, an analysis was applied for identifying the specific correlation of the miR-122 level with HBV DNA, HBeAg, and ALT levels. After liver biopsy, Ishak scoring was utilized for evaluation of the fibrosis stage and the histological activity index (HAI). Results. We confirmed, in the serum, increased miR-122 expression in HBV-infected patients and its highest expression in chronic HBV carriers, based on such comparison between the healthy controls and patients. The correlation analysis results were taken as confirmation of the positive relationship of miR-122 with HBV DNA ( r = 0.354 , P = 0.005 ) and ALT ( r = 0.331 , P = 0.009 ). But no correlation of this molecule with HBeAg levels was found ( P = 0.187 ). In comparison with the HBeAg-negative patients, serum miR-122 expression showed an increase in the HBeAg-positive patients ( P = 0.001 ). miR-122 expression, in addition, was of a significant correlation with HAI, but not with the liver fibrosis score. Conclusion. The peak of the serum miR-122 expression normally occurs in the early stage of the progression from the HBV carrier phase to chronic hepatitis to cirrhosis. This molecule can be considered as a marker for evaluation of HBV-caused liver injury.
Databáze: OpenAIRE